Study of TQH3906 for moderate to severe plaque psoriasis
Treatments studied
Part of Skin clinical trials.
This trial tests an oral medication called TQH3906 for people with moderate to severe plaque psoriasis. It aims to see if the drug can improve skin symptoms and is for adults who have not had enough success with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had plaque psoriasis for at least 6 months.
- Your psoriasis covers at least 10% of your body and is rated as moderate to severe by a doctor.
- You are able to use systemic therapy (pills or injections) or light therapy for your psoriasis.
- You agree to use effective birth control during the study and for 30 days after the last dose (if applicable).
- You have not taken certain psoriasis treatments recently, such as biologics, phototherapy, or strong oral medications, as specified by the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, CBP-0276, to see if it improves psoriasis symptoms and quality of life. It is for people with moderate to severe plaque psoriasis who might need stronger treatment.
This trial tests a new study drug called HSK44459 for people with moderate to severe plaque psoriasis. The hope is that the drug can reduce psoriasis symptoms and improve quality of life. Participation involves receiving the study drug and being monitored for safety and effectiveness.
This study looks at how well deucravacitinib works for adults with moderate to severe plaque psoriasis in everyday medical practice. It helps doctors understand the real-world benefits of this treatment.
This trial tests an oral medication called deucravacitinib for people who have both psoriasis and eczema (or psoriasis that looks like eczema) on their skin. The goal is to see if it can help reduce the severity of their plaques and itch.
This study tests a new injection called SHR-1139 for people with moderate-to-severe plaque psoriasis. The goal is to see if it can safely improve your skin condition.
This trial tests a new medication (HS-10374) taken by mouth to see if it is safe and effective for people with moderate to severe plaque psoriasis. It might help reduce the redness, scaling, and thickness of psoriasis plaques.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.